1. Home
  2. |Insights
  3. |Do Not Pass Go: Board Dismisses Claim on Jurisdictional Grounds

Do Not Pass Go: Board Dismisses Claim on Jurisdictional Grounds

Client Alert | 1 min read | 10.20.17

In Elham Ahmadi Construction Company (ASBCA No. 61031), the Board determined it lacked jurisdiction to consider a contractor’s appeal arising from a termination for default and the contractor’s related claim to recover payment for work that was performed and accepted by the Government prior to the termination. First, the Board held that while “a termination for default is both a government claim and contracting officer’s final decision that can be directly appealed to the Board,” a contractor must appeal such termination within the statutorily-mandated 90 days. Because the contractor did not contest the termination until six years after the termination, the Board concluded it lacked jurisdiction to consider the termination’s propriety. Second, the Board concluded that the contractor’s claim – which requested “about $71500 Dollars” – did not constitute a claim because it lacked the required sum certain. The Board explained that qualifiers such as “about” or “at least” make a sum uncertain and deprive the Board of jurisdiction, a reminder to contractors to observe the jurisdictional prerequisites in the Contract Disputes Act and the FAR, or risk forfeiting otherwise viable claims.

Insights

Client Alert | 6 min read | 04.29.26

CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)

On April 10, 2026, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule (2026 CMS Interoperability Standards and Prior Authorization for Drugs, or CMS-0062-P) outlining the agency’s plans to impose new interoperability requirements on payors participating in certain Medicare and Medicaid programs. As described by the agency in a recent press release, the proposed rule “builds on” prior rulemaking by clarifying and enhancing interoperability requirements for payors’ prior authorization processes, specifically those associated with coverage requests for pharmaceutical therapies....